Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate

- Post-menopausal women 18 years of age or above with proven diagnosis of advanced
adenocarcinoma of the breast (locoregionally recurrent or metastatic disease)

- ER-positive and/or PR-positive tumor based on local laboratory results

- HER2-negative tumor based on local laboratory results

- Patients must be appropriate candidates for letrozole therapy (Canada: first-line
patients only)